Analysis of critical factors in evaluation system for multicenter clinical trials sites
1.Department of Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2.National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Liaoning Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenyang 110000, Liaoning Province, China
3.Parexel International (Shanghai) Co., Ltd., Shanghai 200131, China
4.IQVIA (Shanghai) Medical Technology Co., Ltd., Shanghai 200040, China
5.MSD (China) Holding Co., Ltd., Shanghai 200040, China
6.Shanghai WuXi Jinshi Medical Technology Co., Ltd., Shanghai 200131, China
7.Roche (China) Holding Co., Ltd., Shanghai 200131, China
8.Bayer (China) Co., Ltd., Beijing 100020, China
9.AstraZeneca Global R&D (China) Co., Ltd., Shanghai 201203, China
10.Johnson & Johnson (China) Investment Co., Ltd., Shanghai 200040, China
11.Fosun Pharma Technology Development Co., Ltd., Shanghai 200001, China
12.Syneos Health Consulting (Shanghai) Co., Ltd., Shanghai 200030, China
13.Hangzhou Tigermed Consulting Co., Ltd., Hangzhou 310052, Zhejiang Province, China
14.Yaoyanshe (Jiangsu) Medical Technology Co., Ltd., Suzhou 215123, Jiangsu Province, China
收起